Trial · NCT05847452
Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI)
NCT05847452, Unknown, Guy's and St Thomas' NHS Foundation Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI). Trials, record NCT05847452. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05847452
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI)
- NCT number
- NCT05847452
- Status
- Unknown
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Conditions
- Asthma
- Interventions
- Benralizumab
- First posted
- 2023-05-06
- Last updated
- 2023-07-11
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change in the number of inflammatory cells in patients with severe eosinophilic asthma at baseline and after 12 weeks of benralizumab treatment. | 12 weeks | To investigate the changes in the number of inflammatory cells in patients with severe eosinophilic asthma at baseline and after 12 weeks of benralizumab treatment. |
| Primary | The change in the activation status of Type-2 related cells in patients with severe eosinophilic asthma at baseline and after 12 weeks of benralizumab treatment. | 12 weeks | Activation status will be measured by the relative expression of Type 2 inflammatory cells and gene expression |
| Secondary | To investigate changes in epithelial barrier integrity using transepithelial resistance before and after completing treatment with 12 weeks of benralizumab. | 12 weeks | Transepithelial resistance measures changes in voltage across epithelial cells |
| Secondary | To investigate changes in epithelial antiviral responses in untreated vs respiratory virus-infected cells including rhinovirus-16 in epithelial cells collected before and after completing 12 weeks of treatment. | 12 weeks | Gene expression will be measured using RNA sequencing and reported as gene counts |
| Secondary | To investigate changes in antiviral responses of alveolar macrophages to respiratory viruses including rhinovirus-16 in cells collected from the airways before and after completing 12 weeks of treatment. | 12 weeks | To investigate changes in antiviral responses of alveolar macrophages to respiratory viruses including rhinovirus-16 in cells collected from the airways before and after completing 12 weeks of treatment using protein and nucleic acid analyses. |
| Secondary | To investigate changes in epithelial responses to pro-inflammatory cytokines/chemokines in cells collected before and after treatment. | 12 weeks | To investigate changes in epithelial responses to pro-inflammatory cytokines/chemokines in cells collected at baseline and after treatment. |
| Secondary | To investigate changes in Type 2 inflammation in peripheral airways by collecting bronchoalveolar lavage fluid before and after treatment for nucleic acid and protein analyses. | 12 weeks | Change in the cellular proportions of Type 2 inflammatory cells will be measured using RNA sequencing and reported as gene counts |
| Secondary | To investigate changes in peripheral airway dysfunction before and after treatment by measuring impulse oscillometry. | 12 weeks | Impulse oscillometry will be measured as resistance and impedance |
| Secondary | To investigate the change in FeNO levels before and after treatment. | 12 weeks | FeNO will be measured in parts per billion (ppb) |
| Secondary | Change in routine full blood counts including eosinophil and basophil numbers. | Regular timepoints during 12 weeks | Change in routine full blood counts including eosinophil and basophil numbers at baseline and following 12 weeks of treatment. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05847452
GET https://conductscience.org/api/trials/v1/NCT05847452/registered